Evelo Biosciences, Inc. (EVLO) Research

Evelo Biosciences, Inc. is a biotechnology firm dedicated to identifying and advancing oral biologic therapies for various inflammatory conditions and oncological diseases. Its pipeline includes EDP1815, a whole-microbe compound designed to address inflammatory ailments, currently undergoing Phase 2 clinical trials for conditions such as psoriasis and atopic dermatitis, and also being evaluated for the hyperinflammatory reaction associated with COVID-19. Additional developments include EDP1867, an inactivated oral biologic in Phase 1b for inflammatory diseases; EDP2939, an investigational oral biologic based on extracellular vesicles targeting inflammatory diseases; and EDP1908, a drug candidate focused on cancer. Established in 2014, Evelo Biosciences, Inc. operates from its headquarters in Cambridge, Massachusetts.

Market snapshot

Symbol
EVLO
Price
$0.00
Day change
0.00%
Market cap
$1.9K
P/E ratio
-0.00x
52-week range
0.0001-0.0006
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Aridis Pharmaceuticals, Inc. (ARDS)
  • Biostax Corp. (BTAX)
  • HST Global, Inc. (HSTC)
  • iCoreConnect Inc. (ICCT)
  • Infinity Pharmaceuticals, Inc. (INFIQ)
  • Life Stem Genetics Inc. (LIFS)
  • PaxMedica, Inc. Common Stock (PXMD)
  • Sector 10, Inc. (SECI)

Recent insider activity

  • Bodmer Mark — M-Exempt (6625 shares) on 2023-11-07
  • Bodmer Mark — S-Sale (3163 shares) on 2023-11-08
  • Bodmer Mark — M-Exempt (6625 shares) on 2023-11-07
  • McHale Duncan — M-Exempt (6500 shares) on 2023-11-07
  • McHale Duncan — S-Sale (3103 shares) on 2023-11-08

Open Evelo Biosciences, Inc. (EVLO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.